We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences’ daily oral HIV blockbuster Biktarvy has shown success as a long-term treatment, demonstrating continued high efficacy and strong viral suppression in two phase 3 trials that conducted years of follow-up. Read More
Pfizer and French drugmaker Valneva have initiated a new phase 2 study evaluating VLA15, their experimental vaccine for Lyme disease — and say this is likely to be the last one before the candidate progresses to phase 3 trials. Read More
Merck and Ridgeback Biotherapeutics have said their experimental COVID-19 antiviral MK-4482 (molnupiravir) significantly reduced infection after five days of treatment in a clinical trial. Read More
According to Lilly, tirzepatide reduced blood sugar levels by 2.09 percent at 5 mg, 2.37 percent at 10 mg and 2.46 percent at 15 mg, vs. 1.86 percent for 1 mg of Ozempic. Read More
The UK’s RECOVERY trial, which is assessing multiple potential COVID-19 treatments, has stopped enrollment in its arm evaluating colchicine, an anti-inflammatory drug used to treat gout. Read More
Merck’s anti-parasitic drug Stromectol (ivermectin) did not help speed recovery in patients with mild COVID-19, researchers in Cali, Colombia, found in a small clinical trial. Read More
“While we are disappointed with the recommendation … We are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients,” said Vir Biotechnology CEO George Scangos. Read More
Worldwide trials of the shot have shown wide variations in efficacy rates, and the company has faced criticism for a lack of transparency regarding its trial findings. Read More
Eli Lilly said its investigational drug, tirzepatide, reduced blood sugar and body weight in adults with type 2 diabetes significantly more than Novo Nordisk’s blockbuster Ozempic (semaglutide), in a head-to-head clinical study. Read More
Indian drugmaker Bharat Biotech has announced that its COVID-19 vaccine candidate, Covaxin (BBV152), proved to be 80.6 percent effective in the initial interim analysis of its late-stage clinical trials. Read More
Merck is planning to launch a new late-stage trial of an experimental COVID-19 treatment, MK-7110 (CD24Fc), because the previous phase 3 study enrolled too few participants to support regulatory clearance from the FDA. Read More